文献速递物质与行为成瘾

口服司美格鲁肽治疗酒精使用障碍的随机临床试验

Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial.
PubMed 文献 · Am J Psychiatry · 2026-07-29

司美格鲁肽未显著减少实验室诱发的渴求或每日饮酒量,但显著减少重度饮酒天数、每次饮酒日饮酒量、自然情境渴求和大麻使用天数,并显著降低酒精相关后果及风险饮酒等级。

要点

  • 司美格鲁肽未显著降低实验室诱发的酒精渴求或每日饮酒量。
  • 司美格鲁肽显著减少重度饮酒天数(b=-0.580, 95%CI=-1.012, -0.148)。
  • 司美格鲁肽还显著减少每次饮酒日饮酒量、自然情境渴求及大麻使用天数。

核心结论

  • 口服司美格鲁肽未显著减少实验室诱发的酒精渴求或每日饮酒量,但显著减少重度饮酒天数、每次饮酒日饮酒量、自然情境渴求和大麻使用天数。
  • 司美格鲁肽组比安慰剂组有显著更多参与者将风险饮酒等级降低至少一个等级(Wald χ2=4.01)。
  • 研究结果支持继续开发司美格鲁肽用于酒精使用障碍。

研究设计与样本

  • 参与者随机接受口服司美格鲁肽(3mg/日4周,后7mg/日4周)或安慰剂,共8周。
  • 主要结局为第6周实验室酒精线索诱发的渴求;关键预注册次要结局为治疗最后4周的重度饮酒天数和每日饮酒量。

主要发现

  • 司美格鲁肽未显著减少实验室评估的渴求或每日饮酒量。
  • 司美格鲁肽显著减少重度饮酒天数(b=-0.580, 95%CI=-1.012, -0.148)。
  • 司美格鲁肽显著减少每次饮酒日饮酒量(b=-1.177, 95%CI=-2.307, -0.047)。
  • 司美格鲁肽显著减少自然情境酒精渴求(b=-2.195, 95%CI=-4.174, -0.216)和大麻使用天数(b=-1.434, 95%CI=-2.568, -0.301)。
  • 司美格鲁肽降低酒精相关后果的速率显著大于安慰剂(b=-4.618, 95%CI=-8.651, -0.585)。

关键数值与推荐

  • 司美格鲁肽组比安慰剂组有显著更多参与者将风险饮酒等级降低至少一个等级(Wald χ2=4.01)。
  • 重度饮酒天数效应量b=-0.580(95%CI=-1.012, -0.148)。
  • 每次饮酒日饮酒量效应量b=-1.177(95%CI=-2.307, -0.047)。
  • 自然情境酒精渴求效应量b=-2.195(95%CI=-4.174, -0.216)。
  • 酒精相关后果效应量b=-4.618(95%CI=-8.651, -0.585)。

临床怎么用

  • 对于中重度酒精使用障碍患者,口服司美格鲁肽可能有助于减少重度饮酒天数和每次饮酒量。
  • 司美格鲁肽可能同时减少自然情境下的酒精渴求及酒精相关负面后果。
  • 司美格鲁肽可能降低风险饮酒等级,但需进一步研究确认其临床地位。

局限性

  • 治疗时长仅8周,长期效果未知。
  • 主要结局(实验室诱发渴求)未达显著,需谨慎解读次要结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Accumulating preclinical and observational evidence suggests that glucagon-like peptide-1 receptor agonists, including semaglutide, reduce alcohol consumption. This phase 2 double-blind, randomized, parallel-arm trial evaluated the effects of oral semaglutide on alcohol craving and consumption among treatment-seeking adults with alcohol use disorder (AUD). METHODS: Fifty individuals with moderate to severe AUD were randomized to receive semaglutide (3 mg/day for 4 weeks, then 7 mg/day for 4 weeks) or placebo for 8 weeks. The primary outcome was laboratory-based alcohol cue-elicited craving at week 6. Key preregistered secondary outcomes were heavy drinking days and drinks per day during the last 4 weeks of treatment. Effects on other alcohol consumption measures, naturalistic alcohol craving, alcohol-related negative consequences, World Health Organization risk drinking level, and cannabis use were also explored. RESULTS: Semaglutide did not significantly reduce laboratory-assessed craving or drinks per day compared with placebo, but significantly reduced heavy drinking days (b=-0.580, 95% CI=-1.012, -0.148). Semaglutide also significantly reduced drinks per drinking day (b=-1.177, 95% CI=-2.307, -0.047), naturalistic alcohol craving (b=-2.195, 95% CI=-4.174, -0.216), and cannabis use days (b=-1.434, 95% CI=-2.568, -0.301). Semaglutide reduced alcohol-related consequences at a significantly greater rate than placebo (b=-4.618, 95% CI=-8.651, -0.585). Significantly more participants in the semaglutide group than the placebo group reduced their risk drinking level by one or more levels (Wald χ2=4.01). CONCLUSIONS: These findings confirm previous results among non-treatment seekers with less severe AUD and suggest that continued development of semaglutide for AUD is warranted.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Schacht JP, Sakai JT, Raymond K, et al. Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial. Am J Psychiatry. 2026. PMID: 42522065. doi:10.1176/appi.ajp.20260003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。